E. V. Titova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. V. Titova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Irina Mikhailovna Madaeva
Scientific centre for Family Health and Human Reproduction Problems
4 shared publications - Olga Nikolaevna Berdina
Scientific centre for Family Health and Human Reproduction Problems
4 shared publications - Lyubov Ilijinichna Kolesnikova
Scientific centre for Family Health and Human Reproduction Problems
3 shared publications - Sergey Ivanovich Kolesnikov
Scientific Centre for Family Health and Human Reproduction Problems, 664003 Irkutsk, Russia
3 shared publications - Leonid Fedorovich Sholokhov
Scientific centre for Family Health and Human Reproduction Problems
2 shared publications - Nadezhda A. Kurashova
Scientific centre for Family Health and Human Reproduction Problems
2 shared publications
Latest Publications
- 1 June 2024
- Published by Pleiades Publishing Ltd in Advances in Gerontology
- Vol. 14 (2) , 61-67
Growth Differentiation Factor GDF 15 (“Protein of Senility”) under Conditions of Oxidative Stress and Intermittent Nocturnal Hypoxia in Patients with Sleep Apnea Syndrome
The main pathophysiological triggers of obstructive sleep apnea (OSA) syndrome are oxidative stress and hypoxia. These factors cause cellular and molecular disorders that characterize the aging process. The fact that the blood content of the differentiating protein GDF-15 (the “protein of senility”) increases with age, which was revealed by a number of researchers, arouses interest in its assessment in patients with OSA. Thus, the purpose of this study is to evaluate changes in the content of GDF-15 under conditions of oxidative stress and intermittent nocturnal hypoxia with normalization of the nocturnal oxygen gradient in patients with OSA. The study involves 30 men aged 45–55 years with moderate OSA (main group, MG1) and 35 men of the same age without OSA (control group, CG). The MG1 patients are prescribed aРАР therapy (automatic positive airway pressure) during sleep for 6 months. These patients after treatment make up the second main group, MG2. Blood is taken from all the subjects in the morning to determine the content of lipid-peroxidation products and components of antioxidant defense (LPO-AOD) and GDF-15. The following methods are used to evaluate the results: questionnaires, polysomnographic monitoring, spectrometric and radioimmunoassay methods, and statistical analysis. According to the results, an imbalance of the LPO-AOD system with the predominance of oxidation processes in MG1 is revealed demonstrating the coefficient of oxidative stress, which statistically significantly decreases with the elimination of hypoxia and improvement of sleep structure. GDF-15 demonstrates significant differences between MG1 and CG patients with a predominance of content in the group of MG1 patients with OSA. In comparison with the indicators of MG2, no statistical differences are revealed.
- 1 June 2024
- Published by Pleiades Publishing Ltd in Advances in Gerontology
- Vol. 14 (2) , 61-67
Growth Differentiation Factor GDF 15 (“Protein of Senility”) under Conditions of Oxidative Stress and Intermittent Nocturnal Hypoxia in Patients with Sleep Apnea Syndrome
The main pathophysiological triggers of obstructive sleep apnea (OSA) syndrome are oxidative stress and hypoxia. These factors cause cellular and molecular disorders that characterize the aging process. The fact that the blood content of the differentiating protein GDF-15 (the “protein of senility”) increases with age, which was revealed by a number of researchers, arouses interest in its assessment in patients with OSA. Thus, the purpose of this study is to evaluate changes in the content of GDF-15 under conditions of oxidative stress and intermittent nocturnal hypoxia with normalization of the nocturnal oxygen gradient in patients with OSA. The study involves 30 men aged 45–55 years with moderate OSA (main group, MG1) and 35 men of the same age without OSA (control group, CG). The MG1 patients are prescribed aРАР therapy (automatic positive airway pressure) during sleep for 6 months. These patients after treatment make up the second main group, MG2. Blood is taken from all the subjects in the morning to determine the content of lipid-peroxidation products and components of antioxidant defense (LPO-AOD) and GDF-15. The following methods are used to evaluate the results: questionnaires, polysomnographic monitoring, spectrometric and radioimmunoassay methods, and statistical analysis. According to the results, an imbalance of the LPO-AOD system with the predominance of oxidation processes in MG1 is revealed demonstrating the coefficient of oxidative stress, which statistically significantly decreases with the elimination of hypoxia and improvement of sleep structure. GDF-15 demonstrates significant differences between MG1 and CG patients with a predominance of content in the group of MG1 patients with OSA. In comparison with the indicators of MG2, no statistical differences are revealed.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (5) , 118-124
Changes the level of differentiating growth factor — GDF 15 in patients with sleep apnea syndrome after aPAP-therapy: pilot study
OBJECTIVE Comparative assessment of the level of differentiating growth factor 15 (GDF 15 ) against the background of a 6-month course of respiratory support in the mode of automatic positive pressure in the airways therapy (aPAP therapy) in patients with obstructive sleep apnea syndrome (OSA). MATERIAL AND METHODS 59 men participated in the study, the average age was 51.9±2.4 years. The main group (MG1) consisted of 30 patients with a verified diagnosis of moderate OSA. 29 men of comparable age and body weight made up the control group (CG) without an objectively confirmed diagnosis of OSA. After the stage of introduction into the study, the type of respiratory support with individual pressure settings was selected for patients with MG1. After 6 months of aPAP therapy with high compliance (at least 85%), the same patients who made up MG2 after treatment underwent repeated polysomnography (PSG) and the GDF 15 content was evaluated. Methods: questionnaire, examination, polysomnography, enzyme immunoassay of blood serum to determine the content of GDF 15. RESULTS A 6-month course of aPAP therapy with a high degree of compliance significantly improved the sleep structure and breathing pattern: the representation of NREM 3 increased from 79.2±15.6 to 102.6±21.6 minutes and the REM phase from 56.9± 13.6 to 115.6±26.8. Episodes of apnea were eliminated — apnea-hypopnea index decreased from 21.1 [17.3; 39.1] to 2.5 [1.8; 4.6] and the average values of SaO2 increased from 85.9% to 91.5%. At the same time, a statistically significant excess of GDF 15 was revealed in MG1 — 20.4 [14.16; 31.71] and MG2 — 17.2 [13.63; 24.44]) in comparison with CG — 13.65 [10.7; 17.09]. Despite the lack of statistical significance, a change in the level of GDF 15 was revealed in the form of a decrease in its concentration after a 6-month course of aPAP therapy. CONCLUSION A 6-month course of aPAP therapy made it possible to eliminate intermittent nocturnal hypoxia and improve sleep structure in patients with OSA, as well as reduce the content of GDF 15 protein in blood serum in patients with OSA. However, the tendency to decrease the content of this protein, despite the lack of statistical reliability, confirms the effectiveness of OSA therapy and the possibility of preventing early and pathological aging from the standpoint of somnology and molecular biogerontology.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (5) , 118-124
Changes the level of differentiating growth factor — GDF 15 in patients with sleep apnea syndrome after aPAP-therapy: pilot study
OBJECTIVE Comparative assessment of the level of differentiating growth factor 15 (GDF 15 ) against the background of a 6-month course of respiratory support in the mode of automatic positive pressure in the airways therapy (aPAP therapy) in patients with obstructive sleep apnea syndrome (OSA). MATERIAL AND METHODS 59 men participated in the study, the average age was 51.9±2.4 years. The main group (MG1) consisted of 30 patients with a verified diagnosis of moderate OSA. 29 men of comparable age and body weight made up the control group (CG) without an objectively confirmed diagnosis of OSA. After the stage of introduction into the study, the type of respiratory support with individual pressure settings was selected for patients with MG1. After 6 months of aPAP therapy with high compliance (at least 85%), the same patients who made up MG2 after treatment underwent repeated polysomnography (PSG) and the GDF 15 content was evaluated. Methods: questionnaire, examination, polysomnography, enzyme immunoassay of blood serum to determine the content of GDF 15. RESULTS A 6-month course of aPAP therapy with a high degree of compliance significantly improved the sleep structure and breathing pattern: the representation of NREM 3 increased from 79.2±15.6 to 102.6±21.6 minutes and the REM phase from 56.9± 13.6 to 115.6±26.8. Episodes of apnea were eliminated — apnea-hypopnea index decreased from 21.1 [17.3; 39.1] to 2.5 [1.8; 4.6] and the average values of SaO2 increased from 85.9% to 91.5%. At the same time, a statistically significant excess of GDF 15 was revealed in MG1 — 20.4 [14.16; 31.71] and MG2 — 17.2 [13.63; 24.44]) in comparison with CG — 13.65 [10.7; 17.09]. Despite the lack of statistical significance, a change in the level of GDF 15 was revealed in the form of a decrease in its concentration after a 6-month course of aPAP therapy. CONCLUSION A 6-month course of aPAP therapy made it possible to eliminate intermittent nocturnal hypoxia and improve sleep structure in patients with OSA, as well as reduce the content of GDF 15 protein in blood serum in patients with OSA. However, the tendency to decrease the content of this protein, despite the lack of statistical reliability, confirms the effectiveness of OSA therapy and the possibility of preventing early and pathological aging from the standpoint of somnology and molecular biogerontology.
- 15 December 2023
- Published by Springer Nature in The European Physical Journal Special Topics
- Vol. 233 (3) , 699-703
Pattern of “sleep spindles” in obstructive sleep apnea patients
- 15 December 2023
- Published by Springer Nature in The European Physical Journal Special Topics
- Vol. 233 (3) , 699-703
Pattern of “sleep spindles” in obstructive sleep apnea patients
- 5 June 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (5) , 110-114
Activity of the telomerase complex before and after CPAP therapy in patients with obstructive sleep apnea syndrome
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка активности теломеразного комплекса у пациентов с синдромом обструктивного апноэ сна (СОАС) на фоне СИПАП-терапии (Continuous Positive Airway Pressure — CPAP). МАТЕРИАЛ И МЕТОДЫ В соответствии с целями этапов исследования теломеро-теломеразных взаимоотношений сохранялся единый дизайн исследования, описанный ранее. Основную группу (ОГ1) составили 35 мужчин, средний возраст 53,4 (45,5—60,1) года, с характерными жалобами, указывающими на вероятность СОАС согласно данным анкетирования и последующего полисомнографического мониторинга (ПСГ). ОГ2 составили эти же пациенты после 6 мес респираторной поддержки в режиме СИПАП-терапии. Забор крови проводился после первого диагностического ПСГ и после 6 мес СИПАП утром после второй ПСГ. Контрольную группу (КГ) составили 26 мужчин, сопоставимых по возрасту и наличию хронических заболеваний, которым также были проведены анкетирование, ПСГ и произведен забор биоматериала. Все участники подписали информированное согласие. РЕЗУЛЬТАТЫ В результате анкетирования по шкале STOP-BANG, проведенного до ПСГ, все пациенты ОГ1 имели баллы от 5 до 8 по Эпвортской шкале — >5 баллов. Проведенная в течение 6 мес СИПАП-терапия устранила эпизоды апноэ и сопровождающую их десатурацию. ИАГ снизился с 20,1 до 6,4 события в час, индекс десатурации — с 15,6 до 7,1 события в час (ОГ2). Выявлены статистически достоверные различия в изменении активности теломеразного комплекса, которые после лечения значимо превышают значения этих показателей до лечения. Так, обратная транскриптаза (TERT) составила 0,04 (0,009; 0,06) в ОГ1, после лечения — 0,07 (0,06; 0,09) в ОГ2 и 0,134 (0,009; 0,18) в КГ; белок 1, ассоциированный с теломеразой (ТЕР1), — 0,06 (0,03;0,09), 0,07 (0,05;0,09) и 0,136 (0,04; 0,17) соответственно. Однако, несмотря на активацию теломеразного комплекса на фоне СИПАП-терапии у пациентов с СОАС, в КГ его активность является значимо выше в сравнении с ОГ. ЗАКЛЮЧЕНИЕ При СОАС, сопровождаемом интермиттирующей гипоксией, выявлено снижение активности теломеразного комплекса. Устранение ночной гипоксии и улучшение дыхания во время сна сопровождается повышением активности компонентов теломеразного комплекса.
- 5 June 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (5) , 110-114
Activity of the telomerase complex before and after CPAP therapy in patients with obstructive sleep apnea syndrome
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка активности теломеразного комплекса у пациентов с синдромом обструктивного апноэ сна (СОАС) на фоне СИПАП-терапии (Continuous Positive Airway Pressure — CPAP). МАТЕРИАЛ И МЕТОДЫ В соответствии с целями этапов исследования теломеро-теломеразных взаимоотношений сохранялся единый дизайн исследования, описанный ранее. Основную группу (ОГ1) составили 35 мужчин, средний возраст 53,4 (45,5—60,1) года, с характерными жалобами, указывающими на вероятность СОАС согласно данным анкетирования и последующего полисомнографического мониторинга (ПСГ). ОГ2 составили эти же пациенты после 6 мес респираторной поддержки в режиме СИПАП-терапии. Забор крови проводился после первого диагностического ПСГ и после 6 мес СИПАП утром после второй ПСГ. Контрольную группу (КГ) составили 26 мужчин, сопоставимых по возрасту и наличию хронических заболеваний, которым также были проведены анкетирование, ПСГ и произведен забор биоматериала. Все участники подписали информированное согласие. РЕЗУЛЬТАТЫ В результате анкетирования по шкале STOP-BANG, проведенного до ПСГ, все пациенты ОГ1 имели баллы от 5 до 8 по Эпвортской шкале — >5 баллов. Проведенная в течение 6 мес СИПАП-терапия устранила эпизоды апноэ и сопровождающую их десатурацию. ИАГ снизился с 20,1 до 6,4 события в час, индекс десатурации — с 15,6 до 7,1 события в час (ОГ2). Выявлены статистически достоверные различия в изменении активности теломеразного комплекса, которые после лечения значимо превышают значения этих показателей до лечения. Так, обратная транскриптаза (TERT) составила 0,04 (0,009; 0,06) в ОГ1, после лечения — 0,07 (0,06; 0,09) в ОГ2 и 0,134 (0,009; 0,18) в КГ; белок 1, ассоциированный с теломеразой (ТЕР1), — 0,06 (0,03;0,09), 0,07 (0,05;0,09) и 0,136 (0,04; 0,17) соответственно. Однако, несмотря на активацию теломеразного комплекса на фоне СИПАП-терапии у пациентов с СОАС, в КГ его активность является значимо выше в сравнении с ОГ. ЗАКЛЮЧЕНИЕ При СОАС, сопровождаемом интермиттирующей гипоксией, выявлено снижение активности теломеразного комплекса. Устранение ночной гипоксии и улучшение дыхания во время сна сопровождается повышением активности компонентов теломеразного комплекса.